Jiin Felgner, Elizabeth Clarke, Jenny E Hernandez-Davies, Sharon Jan, Ariel Wirchnianski, Aarti Jain, Rie Nakajima, Algimantas Jasinskas, Erwin Strahsberger, Kartik Chandran, Steven Bradfute, D Huw Davies
Currently, there are two approved vaccine regimens designed to prevent Ebola virus (EBOV) disease (EVD). Both are virus-vectored, and concerns about cold-chain storage and pre-existing immunity to the vectors warrant investigating additional vaccine strategies. Here, we have explored the utility of adjuvanted recombinant glycoproteins (GPs) from ebolaviruses Zaire (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) for inducing antibody (Ab) and T cell cross-reactivity. Glycoproteins expressed in insect cells were administered to C57BL/6 mice as free protein or bound to the surface of liposomes, and formulated with toll-like receptor agonists CpG and MPLA (agonists for TLR 9 and 4, respectively), with or without the emulsions AddaVax or TiterMax...
March 6, 2024: Antiviral Research